It looks like nothing was found at this location. Maybe try one of the links below or a search?
Popular Articles:
-
Response to EPO consultation: Don’t impose oral proceedings by videoconference
-
Quality at the EPO – One Modest and one Serious Proposal
-
‘Opposition against Unitary Patent comes from fearful lawyers and critics who only have a theoretical interest’
-
Leading German patent law firms criticize European Patent Office
-
UPC: four reasons on why the PPA is not legally in force
-
The EPO’s Vision (V) – Trust
Recent Articles:
-
UPC “saisie-contrefaçon” Part II: the “OERLIKON” case
-
UPC “saisie-contrefaçon” Part I: the texts
-
The Role of Scientific Advisers in the English Patents Court
-
Trying to Make Sense of the Oracle of G 2/21: T 116/18 vs. T 681/21
-
Patent case: NanoString Technologies vs. 10x Genomics and President and Fellows of Harvard College, UPC
-
Patent case: Judgment no. 141/2023 dated 5 December 2023, Spain
Random Articles:
-
The Innovation Act Would Bring More U.S. Patent Reform
-
Novartis v. Actavis , Oslo District Court (Oslo tingrett), 10 February 2011
-
An Update on China’s Specialized IP Courts
-
No stay as Alzheimer antibody patent proceeds to trial
-
The Losartan Case in Belgium: One SPC Too Far?
-
Patent case: Re Boehringer Ingelheim Pharma GmbH & Co. KG & Patents Acts, Ireland
-
Neurim under fire again? – The Advocate General’s opinion in the Santen referral (C-673/18)
-
Finally the ‘final’ version of the Rules of Procedure of the Unified Patent Court
-
To Be or Not To BE SEPs
-
Brazilian government resurrects its Partnership for Productive Development (PDP) program. A new threat to pharma IP rights?